scPharmaceuticals (NASDAQ:SCPH) Issues Earnings Results

scPharmaceuticals (NASDAQ:SCPH) issued its quarterly earnings data on Wednesday. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.04, Zacks reports. scPharmaceuticals had a negative return on equity of 244.93% and a negative net margin of 264.60%.

scPharmaceuticals Stock Performance

Shares of NASDAQ SCPH traded down $0.01 during midday trading on Wednesday, reaching $3.04. The company’s stock had a trading volume of 396,544 shares, compared to its average volume of 320,838. scPharmaceuticals has a 12-month low of $2.75 and a 12-month high of $5.70. The firm has a 50 day moving average price of $3.30 and a 200-day moving average price of $3.81. The stock has a market capitalization of $152.12 million, a P/E ratio of -1.60 and a beta of 0.40. The company has a debt-to-equity ratio of 1.66, a current ratio of 8.08 and a quick ratio of 6.89.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of scPharmaceuticals in a research note on Monday, March 3rd.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.